Suppr超能文献

癌症诊断前后的糖尿病护理管理模式:一项 SEER-Medicare 匹配队列研究。

Diabetes care management patterns before and after a cancer diagnosis: A SEER-Medicare matched cohort study.

机构信息

Division of General Internal Medicine, Department of Medicine, Weill Cornell Medicine, New York, New York.

Division of Hematology and Oncology, Department of Medicine, Weill Cornell Medicine, New York, New York.

出版信息

Cancer. 2020 Apr 15;126(8):1727-1735. doi: 10.1002/cncr.32728. Epub 2020 Jan 30.

Abstract

BACKGROUND

Diabetes places patients with cancer at an increased risk of infections, hospitalizations, and mortality. The objective of the current study was to characterize diabetes care management patterns among patients with cancer in the year before and, separately, after cancer diagnosis. The authors hypothesized that diabetes care declines after a diagnosis of cancer.

METHODS

The Surveillance, Epidemiology, and End Results (SEER) cancer registry linked to Medicare claims data was used. The authors included diabetic beneficiaries aged ≥65 years who were diagnosed with incident, nonmetastatic breast, prostate, or colorectal cancer between 2008 and 2013. Controls were diabetic Medicare beneficiaries in SEER regions who did not have cancer. Cases were matched to controls based on age, sex, Charlson Comorbidity Index, and diabetes severity. Primary outcomes were diabetes care received over 12 months: 1) hemoglobin A1c testing; 2) eye examination; and 3) low-density lipoprotein testing. Using a difference-in-difference (DID) approach, the authors examined use differences 12 months before to after diagnosis for patients with cancer and controls. To avoid capturing testing related to diagnosis and not diabetes management, the authors implemented a 90-day washout period (45 days before and/or after diagnosis).

RESULTS

A total of 32,728 diabetic patients with cancer and 32,728 matched noncancer controls were included. After diagnosis, patients with cancer were found to have modest, but significantly lower, rates of diabetes care use compared with controls. Patients with cancer had greater declines in hemoglobin A1c testing (DID, 2.4%; 95% CI, 1.7%-3.0%), low-density lipoprotein testing (DID, 4.3%; 95% CI, 3.6%-5.0%), and receipt of all diabetes indicators (DID, 2.7%; 95% CI, 1.8%-3.5%) 12 months before to after diagnosis.

CONCLUSIONS

Compared with controls, less diabetes care use was observed among patients with cancer in the year after diagnosis. Understanding and addressing the reasons for this may improve outcomes in this population.

摘要

背景

糖尿病使癌症患者面临更高的感染、住院和死亡风险。本研究的目的是描述癌症患者在癌症诊断前和诊断后一年的糖尿病管理模式。作者假设癌症诊断后糖尿病管理会下降。

方法

使用监测、流行病学和最终结果(SEER)癌症登记处与医疗保险索赔数据进行关联。作者纳入了 2008 年至 2013 年间诊断为非转移性乳腺癌、前列腺癌或结直肠癌的年龄≥65 岁的糖尿病受益患者。对照者为 SEER 地区未患癌症的糖尿病医疗保险受益患者。病例根据年龄、性别、Charlson 合并症指数和糖尿病严重程度与对照者进行匹配。主要结局为 12 个月内接受的糖尿病治疗:1)糖化血红蛋白检测;2)眼部检查;3)低密度脂蛋白检测。作者采用差异(DID)法,检查癌症患者和对照者在诊断前 12 个月和诊断后 12 个月的使用差异。为避免捕捉与诊断而非糖尿病管理相关的检测,作者实施了 90 天的洗脱期(诊断前和/或后 45 天)。

结果

共纳入 32728 例癌症糖尿病患者和 32728 例匹配的非癌症对照者。诊断后,与对照者相比,癌症患者的糖尿病治疗使用率较低,但差异具有统计学意义。与对照者相比,癌症患者的糖化血红蛋白检测(DID,2.4%;95%CI,1.7%-3.0%)、低密度脂蛋白检测(DID,4.3%;95%CI,3.6%-5.0%)和所有糖尿病指标的接受率(DID,2.7%;95%CI,1.8%-3.5%)在诊断前 12 个月和诊断后 12 个月均显著下降。

结论

与对照者相比,诊断后癌症患者的糖尿病治疗使用率较低。了解和解决这一问题的原因可能会改善这一人群的结局。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验